当前位置: X-MOL 学术Annu. Rev. Pharmacol. Toxicol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.
Annual Review of Pharmacology and Toxicology ( IF 11.2 ) Pub Date : 2020-01-08 , DOI: 10.1146/annurev-pharmtox-010919-023537
Jill M Pulley 1 , Jillian P Rhoads 1 , Rebecca N Jerome 1 , Anup P Challa 1 , Kevin B Erreger 1 , Meghan M Joly 1 , Robert R Lavieri 1 , Kelly E Perry 1 , Nicole M Zaleski 1 , Jana K Shirey-Rice 1 , David M Aronoff 2, 3
Affiliation  

The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.

中文翻译:

利用我们已经拥有的东西:在现有的Omics数据中发现新的药物重用策略。

药物用途的承诺是加速知识转化为人类疾病的治疗,绕开与药物开发相关的常见挑战,以节省更多时间和成本。由于先前对药物安全性的验证,重新利用具有更大的成功机会,并且可以整合组学。产生假设的组学过程为药物重新利用决策方法提供了有关药物功效和毒性的决策依据。这篇综述总结了以下组学领域中的药物再利用策略和方法:基因组学,表观基因组学,转录组学,蛋白质组学,代谢组学,微生物组学,表观学,前组学和人称组学。尽管每个组学领域都有其特定的优势和局限性,但将组学纳入药物用途领域是其成功的必要条件。
更新日期:2020-04-21
down
wechat
bug